Showing results (261-270 of 295) with videos related to
Sort By:
Pageof 30
European Journal of Cancer (Oxford, England : 1990)|April 9, 2025
Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b studyPhilippe L Bedard, Komal L Jhaveri, Melissa K Accordino, et al.European Urology Focus|October 9, 2020
A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line ChemotherapyChristian Daniel Fankhauser, Ben Tran, Manuel Pedregal, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2025
Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast CancerMitchell J Elliott, Karen Howarth, Sasha Main, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2020
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB TrialNancy U Lin, Virginia Borges, Carey Anders, et al.Nature Cancer|February 5, 2022
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumabScott V Bratman, S Y Cindy Yang, Marco A J Iafolla, et al.JCO Precision Oncology|August 23, 2024
Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With PembrolizumabAlberto Hernando-Calvo, S Y Cindy Yang, Maria Vila-Casadesús, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2025
Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02S A Hurvitz, S Loi, J O'Shaughnessy, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2023
The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non-Small Cell Lung CancerNoura J Choudhury, Jessica A Lavery, Samantha Brown, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2017
A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic CancersUdai Banerji, Emma J Dean, J Alejandro Pérez-Fidalgo, et al.Nature Communications|August 27, 2021
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivityS Y Cindy Yang, Scott C Lien, Ben X Wang, et al.Pageof 30